People with behavioral variant frontotemporal dementia (bvFTD) exhibit behaviors that are considered socially unacceptable. While there is no current cure for FTD, researchers are finding methods to help inhibit some of the negative behaviors associated with FTD. A new study reports impulsivity and negative behaviors are greatly reduced in those with bvFTD when the patient is focused on a task.
Some patients diagnosed with behavioral-variant frontotemporal dementia (bv-FTD) may instead be suffering from a cerebrospinal fluid leak that leads to brain sagging.
Previous TBI increased the risk of frontotemporal dementia in those without a genetic risk factor for FTD. Additionally, researchers found those with FTD tend to be less educated than those with Alzheimer's disease.
With the help of AI, researchers are developing digital biomarkers that use speech data to identify ALS and frontotemporal dementia.
People who later developed Alzheimer's disease scored poorly on memory and logic-based tests, as well as reaction times and grip tests. They were also more likely to have experienced a fall within the past 12 months. Those who developed PSP were twice as likely to experience a fall.
Using neuroimaging and fluid biomarkers from those with the familial form of frontotemporal dementia (FTD), researchers developed models of clinical and biomarker dynamics to determine the temporal sequences of biomarkers and clinical changes in f-FTD before disease progression begins.
Study reveals striking similarities in both behaviors and neuroanatomical changes between people with schizophrenia and behavioral-variant frontotemporal dementia.
Brain folds that form during fetal development may have an impact on the age at which symptoms of frontotemporal dementia occur.
Amyloid fibrils in those with frontotemporal lobar degeneration (FTLD) contain a little-known protein called TMEM106B. Researchers speculate TMEM106B could be found to be the cause of FTLD.
Patients who suffer from frontotemporal dementia with extrapyramidal symptoms have brainstem atrophy and reduced metabolic activity in specific brain regions compared to those with FTD without extrapyramidal symptoms.
PolyP, an inorganic polyphosphate released by astrocytes in people with ALS and frontotemporal dementia contributes to the signature motor neuron death associated with the disease pathologies.
Damage to the multiple demand network, a brain network associated with general intelligence, causes people with dementia to struggle to adapt to changes in their environment